Identification of Plasmatic MicroRNA-206 as New Predictor of Early Recurrence of Atrial Fibrillation After Catheter
Filip Šustr1,2, Táňa Macháčková3, Martin Pešl4
12nd Department of Internal Medicine, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Pekařská 53, 602 00, Brno, Czech Republic.
Insights
Atrial fibrillation (AF) recurrence after catheter ablation (CA) is common. Researchers identified specific plasma microRNAs (miRNAs) that predict early AF recurrence, with hsa-miR-206 showing significant association. This finding could improve patient stratification after CA.
Area of Science:
- Cardiology
- Molecular Biology
- Biomarker Discovery
Background:
- Catheter ablation (CA) is a treatment for symptomatic atrial fibrillation (AF).
- High rates of AF recurrence after CA necessitate better patient stratification.
- Plasmatic microRNAs (miRNAs) are potential biomarkers for predicting AF recurrence.
Purpose of the Study:
- To identify novel plasmatic microRNA (miRNA) biomarkers for predicting atrial fibrillation (AF) recurrence after catheter ablation (CA).
Main Methods:
- Prospective monocentric study of 49 AF patients undergoing CA.
- Plasma miRNA profiling using small RNA sequencing in an exploratory group.
- Validation of selected miRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Main Results:
- 22 differentially expressed miRNAs were identified between patients with and without AF recurrence.
- Plasma levels of hsa-miR-206 were significantly higher in patients with early AF recurrence (within 6 months).
- Increased hsa-miR-206 levels were associated with a 2.65-fold increased risk of early AF recurrence.
Conclusions:
- A set of 22 plasmatic miRNAs can differentiate patients based on AF recurrence post-CA.
- hsa-miR-206 is identified as a novel miRNA biomarker associated with early AF recurrence.
- Further validation in larger, independent cohorts is warranted.
Background:
Catheter ablation (CA) of atrial fibrillation (AF) is indicated in patients with recurrent and symptomatic AF episodes. Despite the strict inclusion/exclusion criteria, AF recurrence after CA remains high. Identification of a novel biomarker that would predict AF recurrence would help to stratify the patients. The aim of the study was to seek novel biomarkers among the plasmatic microRNAs (miRNAs, miRs).
Methods:
A prospective monocentric study was conducted. A total of 49 consecutive AF patients indicated for CA were included. Blood sampling was performed prior to CA. RNA was isolated from plasma using commercial kits. In the exploration phase, small RNA sequencing was performed in ten AF patients (five with and five without AF recurrence) using Illumina instrument. In the validation phase, levels of selected miRNAs were determined using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in all participants.
Results:
Altogether, 22 miRNAs were identified as altered between the groups by next-generation sequencing (using the DESeq2 algorithm). Using qRT-PCR, levels of the five most altered miRNAs (miR-190b/206/326/505-5p/1296-5p) were verified in the whole cohort. Plasma levels of hsa-miR-206 were significantly higher in patients with early (within 6 months) AF recurrence and showed an increase of risk recurrence,2.65 times by every increase in its level by 1 unit in the binary logistic regression.
Conclusion:
We have identified a set of 22 plasmatic miRNAs that differ between the patients with and without AF recurrence after CA and confirmed hsa-miR-206 as a novel miRNA associated with early AF recurrence. Results shall be verified in a larger independent cohort.
More Related Videos
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018